遺傳性血管性水腫治療市場規模、佔有率、成長分析、按治療方法、按給藥途徑、按分銷管道、按最終用途、按地區 - 行業預測，2025-2032 年

2023 年全球遺傳性血管性水腫藥物市場規模價值27 億美元，預計將從2024 年的27.7 億美元成長到2032 年的33.7 億美元，預測期內（2023-2032 年）的複合年成長率為1.1 %。

其在醫療保健領域的市場擴張很大程度上是由於人們越來越認知到治療罕見疾病，特別是遺傳性血管性水腫 (HAE) 的必要性。此疾病影響約五萬人中的一人，全球盛行率為十五萬人中的一人。血管性水腫的發生率不斷上升，其特徵是身體各部位突然腫脹，促使美國遺傳性血管性水腫協會等組織加大宣傳力度，倡導新的治療方案和患者支持。最近的調查顯示，醫療保健專業人員報告了治療遺傳性血管性水腫的進展，新的治療方法改善了患者的治療效果和滿意度。在印度，估計有 30,000-50,000 人患有遺傳性血管性水腫，主要由皮膚科醫生、胃腸病學家和臨床過敏專家治療。

目錄

介紹

• 調查目的
• 研究範圍
• 定義

調查方法

• 資訊採購
• 次要和資料資料
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分市場機會分析

市場動態及展望

• 市場概況
• 市場規模
• 市場動態
  • 促進因素和機遇
  • 限制與挑戰
• 波特的分析

主要市場考察

• 關鍵成功因素
• 競爭程度
• 主要投資機會
• 市場生態系統
• 市場吸引力指數（2024 年）
• PESTEL 分析
• 總體經濟指標
• 價值鏈分析
• 定價分析
• 監管格局
• 案例研究
• 技術進步

遺傳性血管性水腫藥物市場規模（依治療）

• 市場概況
• C1 酯酶抑制劑
• 緩激肽B2受體拮抗劑
• 激肽釋放酶抑制劑
• 其他

遺傳性血管性水腫藥物市場規模（依給藥途徑）

• 市場概況
• 靜脈
• 皮下
• 口服

遺傳性血管性水腫藥物市場規模（依分銷管道）

• 市場概況
• 醫院藥房
• 零售藥局
• 其他

遺傳性血管性水腫藥物市場規模（依最終用途）

• 市場概況
• 預防
• 一經請求

遺傳性血管性水腫治療市場規模

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前 5 家公司對比
• 主要企業市場定位（2024年）
• 主要市場參與者所採用的策略
• 近期市場趨勢
• 公司市場佔有率分析（2024 年）
• 主要企業簡介
  • 公司簡介
  • 產品系列分析
  • 按細分市場分析市場佔有率
  • 收益與前一年同期比較（2022-2024 年）

主要企業簡介

• CSL Behring（Australia）
• Takeda Pharmaceutical Company Limited（Japan）
• Pharming Group NV（Netherlands）
• BioCryst Pharmaceuticals, Inc.（USA）
• Ionis Pharmaceuticals, Inc.（USA）
• Sanofi SA（France）
• Adverum Biotechnologies, Inc.（USA）
• KalVista Pharmaceuticals, Inc.（USA）
• Attune Pharmaceuticals, Inc.（USA）
• Arrowhead Pharmaceuticals, Inc.（USA）
• Amgen Inc.（USA）
• BioMarin Pharmaceutical Inc.（USA）
• Catalyst Biosciences, Inc.（USA）
• RUCONEST（Pharming Group NV, Netherlands）
• Haegarda（CSL Limited, Australia）
• Firazyr（Shire plc, UK）
• Dyax Corp.（USA）
• Adverum Biotechnologies, Inc.（USA）
• Amgen Inc.（USA）

結論和建議

Global Hereditary Angioedema Treatment Market size was valued at USD 2.7 billion in 2023 and is poised to grow from USD 2.77 billion in 2024 to USD 3.37 billion by 2032, growing at a CAGR of 2.5% during the forecast period (2025-2032).

Market expansion in the healthcare sector is significantly driven by the growing recognition of the need for treatments for rare disorders, notably hereditary angioedema (HAE). This condition affects approximately 1 in 50,000 individuals, with a global prevalence of 1 in 150,000. The increasing incidence of angioedema attacks, characterized by sudden swelling in various body regions, is leading to heightened awareness efforts by organizations like the US Hereditary Angioedema Association, which advocates for modern treatment options and support for patients. Recent surveys show that healthcare professionals have reported advancements in HAE management, with improved patient outcomes and satisfaction due to novel therapies. In India, an estimated 30,000-50,000 individuals suffer from HAE, predominantly treated by dermatologists, gastroenterologists, and clinical allergists.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Hereditary Angioedema Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Hereditary Angioedema Treatment Market Segmental Analysis

Global Hereditary Angioedema Treatment Market is segmented by Treatment, Route of Administration, Distribution Channel, End Use and region. Based on Treatment, the market is segmented into C1-esterase inhibitor, Bradykinin B2 receptor antagonist, Kallikrein inhibitor and Others. Based on Route of Administration, the market is segmented into Intravenous, Subcutaneous and Oral. Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Retail Pharmacy and Others. Based on End Use, the market is segmented into Prophylaxis and On-demand. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Hereditary Angioedema Treatment Market

The global hereditary angioedema treatment market is significantly driven by a heightened focus on advanced therapeutics aimed at managing these disorders. Researchers and manufacturers worldwide are diligently working to develop and enhance therapies for hereditary angioedema, as evidenced by numerous new medication applications for C1-esterase inhibitors, Bradykinin B2 receptor antagonists, and Kallikrein inhibitors targeting Types I, II, and III HAE. This surge in sophisticated treatment options, coupled with rising awareness and the increasing prevalence of rare diseases, has accelerated market growth. Recent approvals of innovative medications and a promising pipeline for future drug developments further bolster this expansion, alongside the growing impact of severe edema episodes linked to elevated estrogen levels and ACE inhibitor usage.

Restraints in the Global Hereditary Angioedema Treatment Market

The growth of the global hereditary angioedema treatment market is significantly hindered by the frequent misdiagnosis of the condition, often mistaken for common allergies, appendicitis, and irritable bowel syndrome. This misidentification stems from a widespread lack of awareness regarding hereditary angioedema (HAE), resulting in inadequate treatment for those affected. Consequently, many individuals suffering from HAE receive incorrect diagnoses, frequently being categorized under gastrointestinal disorders or non-allergic angioedema, thereby delaying appropriate care. This prevalent issue not only disrupts the treatment process for patients but also stifles advancements and expansion within the hereditary angioedema treatment market as a whole.

Market Trends of the Global Hereditary Angioedema Treatment Market

The Global Hereditary Angioedema (HAE) Treatment market is witnessing significant growth driven by increased awareness of rare conditions and the emergence of innovative therapies. Key catalysts include the introduction of novel therapeutics and pipeline medications, exemplified by recent products like Takhzyro (lanadelumab), which addresses prophylactic HAE treatment. A notable trend is the shift towards oral delivery methods, enhancing patient convenience and minimizing adverse effects compared to traditional treatments. As pharmaceutical companies explore the rare disease sector, the influx of new entrants with promising products suggests a competitive landscape poised for expansion. This dynamic environment is expected to further accelerate market growth and improve treatment accessibility for HAE patients globally.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Landscape
• Case Studies
• Technological Advancement

Global Hereditary Angioedema Treatment Market Size by Treatment & CAGR (2025-2032)

• Market Overview
• C1-esterase inhibitor
• Bradykinin B2 receptor antagonist
• Kallikrein inhibitor
• Others

Global Hereditary Angioedema Treatment Market Size by Route of Administration & CAGR (2025-2032)

• Market Overview
• Intravenous
• Subcutaneous
• Oral

Global Hereditary Angioedema Treatment Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacy
• Retail Pharmacy
• Others

Global Hereditary Angioedema Treatment Market Size by End Use & CAGR (2025-2032)

• Market Overview
• Prophylaxis
• On-demand

Global Hereditary Angioedema Treatment Market Size & CAGR (2025-2032)

• North America (Treatment, Route of Administration, Distribution Channel, End Use)
  • US
  • Canada
• Europe (Treatment, Route of Administration, Distribution Channel, End Use)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Treatment, Route of Administration, Distribution Channel, End Use)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Treatment, Route of Administration, Distribution Channel, End Use)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Treatment, Route of Administration, Distribution Channel, End Use)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• CSL Behring (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pharming Group N.V. (Netherlands)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioCryst Pharmaceuticals, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ionis Pharmaceuticals, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Adverum Biotechnologies, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• KalVista Pharmaceuticals, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Attune Pharmaceuticals, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Arrowhead Pharmaceuticals, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioMarin Pharmaceutical Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Catalyst Biosciences, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• RUCONEST (Pharming Group N.V., Netherlands)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Haegarda (CSL Limited, Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Firazyr (Shire plc, UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dyax Corp. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Adverum Biotechnologies, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations